Isotechnika Pharma Inc IPHAF

My Little Bit

[Brownie52]

I hope you are right klank as it would explain a lot of things. Like you, I really like to see mangement of a company to under promise and then over deliver. My perception of ISA management is that for years it has overpromised and then underdelivered which has led to the long term downward spiral in the share price and shareholder disinterest. It appears to me that the overpromising stopped right after the disappointment of the LUX FDA decision that required them to do another trial which is now ongoing with a stated completion date in May of this year. I take heart in the fact that LUX still has hope in voclosporin for uveitis or they would have cut their losses and ran. Where I have real difficulty with ISA management is their current stance on voclosporin as a treatment for psoriasis. Their position that the psoriasis initiative is Paladin's issue is perplexing. I have not been able to find anything in the public domain that they have given up or sold off the royalty rights for the psorissis indication and if someone has that information I would love to see it. A posting by gerardTV1  on Sept 9/2011 pointed us to a survey that was done by Decision Resources, a well respected medical research company,  that tells us "the majority of surveyed dermatologists in the EU5 indicate that they will prescribe Isotechnika's emerging calcinuerin inhibitor voclosporin following its launch for psoriasis." The survey goes on to say that "By the end of 2014 Decision Resources expects three novel oral systemic agents-voclosporin, tofacitinib and Celgene's phosphodiesterase-4 (PDE-4) inhibitor apremilast - to launch in Europe for the treatment of psoriasis." This appears to be encouraging news for voclosporin yet there is no acknowledgement from either Isotechnika or Paladin. In my mind if the majority of EU5 dermatologists are thinking this way there should be information for shareholders to understand how this launch by the end of 2014 is going to take place. I have found on the Decision Resources website the outlines of studies they have done that tell me that Isotechnica and Paladin are discussed in the study but I do not have access to these studies to better understand what is happening. The website does tell me that 11 drugs in this class are undergoing Phase 2 trials and 4 are undergoing Phase 3 trials. Is voclosporin in one of these trials or have Isotechnika and Paladin dismissed this opportunity despite the dermatologists positive outlook. As a shaerholder in ISA this is information that I should  be privy to. Hopefully they are trying to keep expectations down. It would result in a very positive pop to the share price if this indication is still being pursued. I see the vultures circling and I am concerned that shareholders will not get anything near full value. I hope I am wrong.